Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsallcareadvantage Ipratropium Prior Auth Coverage |…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 019.2

    Ipratropium (Atrovent) prior authorization and coverage criteria

    Customize your policy alerts

    Sign up for allcareadvantage Policy 019.2 alerts

    Get alerted when Policy 019.2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and coverage criteria for ipratropium (Atrovent) inhalers and nebulizer solution for AllCare Advantage members, including COPD and certain off-label asthma uses. Applies to prescription drug benefit managed by the payer.

    Policy Summary
    Payerallcareadvantage
    PolicyIpratropium (Atrovent) prior authorization and coverage criteria
    Policy CodePolicy 019.2
    Change TypeRoutine review - no material changes
    Effective DateJun 14, 2022
    Last ReviewJun 13, 2024
    Next Review DateJun 13, 2024
    Key ActionObtain prior authorization and document diagnosis and required treatment history (e.g., COPD diagnosis or failed SABA + ICS or leukotriene receptor antagonist for asthma) to support approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration (chronic)
    2/moQL for COPD
    1 fillNebulizer acute fill
    1/moQL HFA inhaler (asthma)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Ipratropium

    Approval Criteria

    Covered when the following criteria tree is satisfied:

    Root

    • Criteria #1: Member has a diagnosis of COPD

      If yes -> Approve x12 months with QL 2 per month; if no -> go to Criteria #2

    • Criteria #2: Documentation supports an acceptable off-label diagnosis

      Acceptable off-label: Asthma -> go to #3; Exercise-induced bronchospasm prophylaxis -> go to #4; if no -> Deny

    • Criteria #3: Request is for ipratropium nebulizer solution for acute asthma exacerbation

      If yes -> Approve x1 fill with QL 1 box; if no -> Deny

    • Criteria #4: Request is for ipratropium HFA inhaler AND documentation shows continued symptoms despite use of a SABA and either an inhaled corticosteroid (ICS) or a leukotriene receptor antagonist

      If yes -> Approve x12 months; QL 1 per month; if no -> Deny

    Ipratropium has not demonstrated effectiveness in long-term management of asthma. Clinical trials and systematic reviews show only small benefits when used alone versus short-acting beta2-agonists and suggest its primary proven role is in chronic obstructive pulmonary disease (COPD). The policy therefore limits chronic asthma use to narrowly defined off-label situations with required documentation of benefit or acute indications.

    Requests are not approved when there is no documentation of COPD or an acceptable off-label diagnosis. Specifically, denials will occur if the member lacks a COPD diagnosis and documentation does not support an off-label indication (asthma or exercise‑induced bronchospasm), or if the request for nebulizer solution or HFA inhaler does not meet the stated criteria (e.g., acute nebulizer use for asthma or documented failure/continued symptoms despite SABA plus ICS or a leukotriene receptor antagonist for HFA inhaler).

    Provider Requirements and Authorization

    Prior Authorization

    Prior authorization required; approvals vary by indication

    Prior authorization is required for ipratropium (Atrovent) and will be approved only when the coverage criteria for the requested indication are met; approvals and duration vary by indication (see criteria tree).

    Step Therapy

    Step requirement — document failure of SABA + ICS or leukotriene antagonist

    For requests for the ipratropium HFA inhaler for asthma, submit documentation that the member has continued symptoms despite use of a short-acting beta agonist (SABA) and either an inhaled corticosteroid (ICS) or a leukotriene receptor antagonist; approval is contingent on this documentation.

    • If documentation of continued symptoms despite SABA + (ICS or leukotriene receptor antagonist) is present → approve x12 months; QL 1 per month.
    • If documentation is not provided → request will be denied.

    Initial Therapy

    Initial Therapy

    Initial approval logic

    Initial approval: Approve if member has COPD (12 months, QL 2 per month) OR if off-label asthma with acute exacerbation requesting nebulizer solution (1 fill, QL 1 box) OR if requesting ipratropium HFA inhaler for off-label asthma with documentation of continued symptoms despite SABA plus ICS or leukotriene receptor antagonist (12 months, QL 1 per month)

    Follow documentation requirements

    Continuation / Renewal Criteria

    Continuation Therapy

    Continuation/renewal approvals for chronic use

    Continuation: For members previously approved under COPD or chronic asthma criteria, approve renewals for 12 months subject to quantity limits

    Quantity limits: 2 per month for COPD approvals; 1 per month for HFA inhaler approvals

    Step Therapy Requirements

    Required documentationAction when documentedCoverage
    Documentation of continued symptoms despite use of a short-acting beta agonist (SABA) and either an inhaled corticosteroid (ICS) or a leukotriene receptor antagonist
    Approve for 12 months
    Quantity limit: 1 per month
    If documentation of continued symptoms is NOT provided
    Deny
    No coverage without required step documentation

    Quantity Limits and Fill Limits

    Quantity limit — Ipratropium (Atrovent)
    DrugIpratropium (Atrovent)
    Quantity limit2 per month
    Approval duration (if COPD)12 months
    Applicable indicationCOPD (including chronic bronchitis or emphysema)
    Quantity limit — Ipratropium HFA inhaler (asthma)
    ProductIpratropium HFA inhaler (for asthma)
    Quantity limit1 per month

    Indications and Definitions

    FDA-approved indication
    FDA-approved indicationTreatment of bronchospasm due to chronic obstructive pulmonary disease (COPD), including chronic bronchitis or emphysema
    ScopeApplies to ipratropium inhalers and solution for inhalation
    Policy noteCover ipratropium for members with COPD or asthma exacerbation who have tried a short-acting beta agonist
    Off-label indications
    Off-label usesAcute bronchospasm (e.g., asthma exacerbation)
    Off-label usesAdjunctive exercise-induced bronchospasm prophylaxis
    Effectiveness note

    Background

    Ipratropium is FDA‑approved for the treatment of bronchospasm due to COPD (including chronic bronchitis or emphysema). It is used off‑label for acute bronchospasm (for example, asthma exacerbations) and as adjunctive prophylaxis for exercise‑induced bronchospasm. Evidence indicates small benefits over short‑acting beta2‑agonists in COPD and potential additive benefit during severe acute asthma exacerbations, but it has not shown effectiveness for long‑term asthma control.

    Policy Summary
    Payerallcareadvantage
    PolicyIpratropium (Atrovent) prior authorization and coverage criteria
    Policy CodePolicy 019.2
    Change TypeRoutine review - no material changes
    Effective DateJun 14, 2022
    Last ReviewJun 13, 2024
    Next Review DateJun 13, 2024
    Key ActionObtain prior authorization and document diagnosis and required treatment history (e.g., COPD diagnosis or failed SABA + ICS or leukotriene receptor antagonist for asthma) to support approval.
    SourceLink
    On This Page
    Coverage Criteria for IpratropiumProvider Requirements and AuthorizationInitial TherapyContinuation / Renewal CriteriaStep Therapy RequirementsQuantity Limits and Fill LimitsIndications and DefinitionsBackground
    Documentation Required

    Required documentation to support diagnosis and prior therapy

    Provide clinical documentation supporting the diagnosis (COPD, asthma, or exercise‑induced bronchospasm) and any prior therapies referenced in the criteria (e.g., SABA, ICS, leukotriene receptor antagonist) to demonstrate the required treatment history.

    • For COPD approvals: documentation of COPD diagnosis to qualify for 12‑month approval with QL 2 per month.
    • For ipratropium HFA inhaler (asthma): documentation of continued symptoms despite SABA and ICS or leukotriene receptor antagonist.
    • For nebulizer solution (acute asthma exacerbation): documentation that the request is for an acute exacerbation to qualify for 1 fill (1 box).
    Denial Risk

    Denial triggers — missing diagnosis or unmet indication criteria

    Requests will be denied if there is no documentation of COPD or an acceptable off‑label diagnosis (asthma or exercise‑induced bronchospasm), or if the specific criteria for nebulizer or HFA inhaler use are not met.

    • No COPD diagnosis documented → deny unless acceptable off‑label diagnosis is documented.
    • Off‑label asthma requests without documentation of acute exacerbation (for nebulizer) or without required failure/continued‑symptom documentation (for HFA inhaler) → deny.
    Approval duration (if criteria met)12 months
    RequirementDocumentation of continued symptoms despite use of a SABA and either an inhaled corticosteroid (ICS) or leukotriene receptor antagonist
    Quantity limit — Ipratropium nebulizer solution
    ProductIpratropium nebulizer solution
    IndicationAcute asthma exacerbation
    Quantity limit1 fill / 1 box
    Approval actionApprove for 1 fill when request is for nebulizer solution for acute asthma exacerbation
    Ipratropium has not demonstrated effectiveness in long-term management of asthma